



#### Q3 2022 Investor Deck

As of September 30, 2022 | Reported on November 3, 2022

#### **Safe Harbor Statements**

Certain statements contained in this presentation are "forward-looking statements" about future events and expectations. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, the continuing impact of the COVID-19 outbreak on the economy and our operations (including temporary clinic closures, shortened business hours and reduced patient demand), our failure to develop or acquire company-owned or managed clinics as rapidly as we intend, our failure to profitably operate companyowned or managed clinics, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage, shortselling strategies and negative opinions posted on the internet which could drive down the market price of our common stock and result in class action lawsuits, our failure to remediate the current or future material weaknesses in our internal control over financial reporting, which could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence, and other factors described in our filings with the SEC, including in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 to be filed with the SEC and subsequently-filed current and quarterly reports. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. We qualify any forwardlooking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

#### **Business Structure**

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.







Quality, convenient, affordable chiropractic care to retail



#### Serving patients seeking pain relief and ongoing health and wellness

© 2022 The Joint Corp. All Rights Reserved.



OUR CLINICS



A proven membership-based, walk-in, no-insurance model in an open bay setting

© 2022 The Joint Corp. All Rights Reserved. 5

## Solid Foundation and Continued Growth





<sup>1</sup> New patient survey completed February 2022.

## Three Enterprise Initiatives to Advance Growth

#### Forging the Chiropractic Dream

Harnessing the Power of Our Data

#### Accelerating the Pace of Clinic Growth









### Upside for Future Growth

\$19.5B growing chiropractic market<sup>1</sup>





# Substantial Opportunity for Market Share Growth

- Annual spending on back pain: \$134B<sup>1</sup>
- Chiropractic care: \$19.5B<sup>2</sup>
- Total chains make up ~4% of chiropractic<sup>3</sup>
- By contrast, dentistry chains (DSOs) account for nearly 12%<sup>4</sup>





<sup>1</sup>JAMA US Healthcare spending by Payer and Health Condition, 1996-2016, March 3, 2020 | <sup>2</sup> IBIS US Industry Report, Chiropractors in the US, March 2022 | <sup>3</sup>Internal Chiropractic Competitive Analysis, August 2019 | <sup>4</sup> Apex Reimbursement Specialists, Inc., 2018

## Only 4.9% of Franchise Concepts Have 500+ Units





Source: FRANdata

e Joint Corp. | NASDAR: JYN7

## JYNT Sales ~2.3x Independent Collections per Clinic



\*2021 Chiropractic Economics Compensation Survey



### Distinguished among Franchise Concepts

Clinics with sales over \$550k: 308 in 2021, up 82% from 2020

#### Together, we're making a statement.





### Market Opportunity: ~1950 Potential Clinics



#### Targeting 1,000 clinics opened by the end of 2023 The Joint Patient Base

With usable addresses

- All 50 States, DC, and Puerto Rico
- All Canadian Provinces and Territories
- 45 Countries on 6 Continents

#### ~1950 Similar Points of Distribution

- Analyze demographics and psychographics
- Model attributes
- Roll across country



# The Joint: Industry Leader with Momentum Building

Companies	<b>Clinics</b> at 9/30/22	Clinics at 12/31/17	Change in Clinics	States	Franchise	Owned/ Managed	Insurance	Private Pay
The Joint Corp.	805	399	406	39	✓	✓		<ul> <li>✓</li> </ul>
Airrosti	161	177	(16)	5		✓	✓	✓
HealthSource Chiropractic	143	295	(152)	35	✓		✓	
100% Chiropractic	93	*	*	17	✓		✓	×
ChiroOne	90	41	49	7		✓	✓	
AlignLife Chiropractic	34	23	11	14	✓	✓	✓	
Chiropractic Company	23	*	*	1		✓	✓	
Aligned Modern Health	20	*	*	1		✓	✓	
NuSpine	19	3	16	9	✓			✓
Chiropractic Partners	12	*	*	1		✓	✓	✓
20 Dollar Chiropractic	11	*	*	3	✓			✓
The BackSpace	10	*	0	2		✓		✓
Chiro Now!	10	*	10	1	✓	✓		✓
ChiroWay	10	8	2	2	✓			✓
Express Chiropractic	6	0	6	1	✓			×
SnapCrack Chiropractic	5	*	*	1	✓			×
Independent Offices	40,501	38,801	1,700	50				

## Opened 38 Clinics in Q3 2022, Up from 33 in Q3 2021







#### **Growing National Footprint**

As of 9/30/2022



# Pipeline for Clinic Openings Remains Strong

Clinics in Active Development<sup>1</sup>



Gross Cumulative Franchise Licenses Sold<sup>1</sup>

841

Dec. 31,

2019

715

Dec. 31,

2018

616

Dec. 31.

2017

962

62% sold by RDs in Q3 2022

Franchise Licenses Sold Annually

69% of clinics supported by 19 RDs as of Sept. 30, 2022

RDs cover 55% of Metropolitan Statistical Areas (MSAs) as of Sept. 30, 2022

Dec. 31,

2020



<sup>1</sup> Of the 1,176 franchise licenses sold as of September 30, 2022, 252 are in active development, 690 are currently operating and the balance represents terminated/closed licenses.

Dec. 31,

2021

1176

Sept. 30,

2022

1118

# **Continued Improvement to Clinic Economics**

More recent cohorts continue to far surpass historical sales growth

#### Approximate Investment of \$300k

- \$200K initial build-out cost
- Franchisee pays
- 7% royalty on gross sales
- \$599/month in software fees
- 2% of gross sales for the National Marketing Fund
- Local marketing expenses
- Assumes breakeven at \$27K to \$30k monthly gross sales<sup>1</sup>
- Franchisee pays \$39.9K per license, prior to year 1 sales
- Improving estimated cash-on-cash return from 5+ years to less than 3.5 years

System-wide Sales & Potential Company-owned/Managed Contribution<sup>1</sup>

(5 yr. avg., \$ in 000s)





<sup>1</sup> Breakeven varies on a clinic-by-clinic basis based on actual gross sales and operating expenses. This represents operating margin excluding income taxes and depreciation.

## Building upon Foundation for Growth



Increase in system-wide sales Q3 2022 over Q3 2021



Increase in comp sales<sup>1</sup> for all clinics >13 months in operation Q3 2022 over Q3 2021 2%

Increase in comp sales<sup>1</sup> for all clinics >48 months in operation Q3 2022 over Q3 2021





<sup>1</sup>Comparable sales include only the sales from clinics that have been open at least 13 or 48 full months and exclude any clinics that have permanently closed. <sup>2</sup> Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

## Tightening 2022 Financial Guidance

\$ in M	2021 Actual	2022 Low Guidance	2022 High Guidance
Revenues	\$80.9	\$100.0	\$102.0
Adjusted EBITDA <sup>1</sup>	\$12.6	\$11.5	\$12.5
New Franchised Clinic Openings	110	110	130
New Company-owned/Managed Clinics <sup>2</sup>	32	30	40



<sup>1</sup> Reconciliation of Adjusted EBITDA to GAAP earnings is included in the appendix. <sup>2</sup> Through a combination of both greenfields and buybacks.

## Driving Long-term Stakeholder Value

People will continue to seek more noninvasive, holistic ways to manage their pain.

We'll be there to treat them.

#### The Joint Corp. 11-yr. CAGR 67%<sup>1</sup> vs. Industry CAGR 5.4%<sup>2\*</sup>





<sup>1</sup> For the period ended Dec. 31, 2021 | <sup>2</sup> June 2021 Kentley Insights Chiropractic Care Market Research Report

21

#### **Driving Brand Awareness**

#### The most powerful brand-building tool is our storefronts.





#### Appendix



Source:

© 2022 The Joint Corp. All Rights Reserved. 23

## Q3 2022 Financial Results

\$ in M <sup>1</sup>	Q3 2022	Q3 2021	Differe	ences
Revenue <ul> <li>Corporate clinics</li> <li>Franchise fees</li> </ul>	\$26.6 15.8 10.8	\$21.0 11.6 9.4	\$5.6 4.2 1.4	27% 36% 15%
Cost of revenue	2.5	2.3	0.2	8%
Sales and marketing	3.5	2.9	0.6	23%
Depreciation and amortization	2.0	1.7	0.3	21%
G&A	18.1	12.8	5.3	41%
Operating Income	0.5	1.3	(0.8)	(63)%
Tax Expense/(Benefit)	(0.0)	(0.6)	0.6	100%
Net Income	0.5	1.9	(1.4)	(75)%
Adj. EBITDA <sup>2</sup>	3.1	3.3	(0.2)	(5)%



<sup>1</sup> Due to rounding, numbers may not add up precisely to the totals.

<sup>2</sup> Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

# YTD 2022 Financial Results as of Sept. 30, 2022

\$ in M <sup>1</sup>	First 9 Mo.s 2022	First 9 Mo.s 2021	Differe	ences
Revenue <ul> <li>Corporate clinics</li> <li>Franchise fees</li> </ul>	\$74.1 42.9 31.2	\$58.8 32.5 26.2	\$15.3 10.4 4.9	26% 32% 19%
Cost of revenue	7.2	6.1	1.1	18%
Sales and marketing	10.7	8.5	2.2	25%
Depreciation and amortization	5.3	4.3	1.1	25%
G&A	50.1	34.5	15.5	45%
Operating Income	0.8	5.3	(4.5)	(85)%
Tax Expense/(Benefit)	0.1	(1.6)	1.7	(106)%
Net Income	0.6	6.9	(6.3)	(91)%
Adj. EBITDA <sup>2</sup>	7.5	10.5	(3.0)	(28)%



<sup>1</sup> Due to rounding, numbers may not add up precisely to the totals.

<sup>2</sup> Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

#### **Executive Team**

Peter D. Holt	Jake Singleton	Jason Greenwood	Charles Nelles	Jorge Armenteros	Eric Simon	Mark Miller	Dr. Steve Knauf
<ul> <li>President &amp; CEG</li> <li>Tasti D-Lite</li> <li>Planet Smoothin</li> <li>Mail Boxes Etc.</li> <li>The UPS Store</li> <li>I Can't Believe It's Yogurt</li> </ul>	• EY	CMO Peter Piper Pizza Robeks Juice Young & Rubicam Group	<ul> <li>CTO</li> <li>American Express Global Business Travel</li> <li>Western Union</li> <li>The Children's Hospital of Denver</li> <li>PacifiCare Health Systems</li> </ul>	SVP, Operations <ul> <li>Togo's</li> <li>Dunkin' Donuts</li> <li>Baskin Robbins</li> <li>Pollo Campero</li> </ul>	<ul> <li>VP, Franchise Sales</li> <li>Aamco</li> <li>Mail Boxes Etc.</li> <li>UPS Store</li> <li>Extreme Pita</li> </ul>	<ul> <li>VP, Real Estate and Construction</li> <li>Veggie Grill</li> <li>Panda Restaurant Group</li> <li>CVS</li> </ul>	<ul> <li>VP of Chiropractic &amp; Compliance</li> <li>Arizona Board of Chiropractic Examiners</li> <li>Northwestern Health Sciences University</li> <li>International Chiropractors Assn.</li> <li>American Chiropractic Assn.</li> <li>Health Care Compliance Assn.</li> </ul>
BA, Univ. of Washin MA, Univ. of Londo	-	MBA, Wayne State Univ. BBA, Eastern Michigan Univ.	BA, University of Phoenix Certified PMP		BA, Univ. of Rhode Island	MBA, Wayne State Univ. BS, Central Michigan Univ.	DC, Northwestern Health Sciences Univ. BS, Northwestern Health Sciences Univ.



#### **Board of Directors**















Matthew E. Rubel	James H. Amos, Jr.	Ronald V. DaVella, CPA	Suzanne M. Decker	Peter D. Holt	Abe Hong	Glenn J. Krevlin
Lead Director, 2017	Director, 2015	Director, 2014	Director, 2017	Director, 2016	Director, 2018	Director, 2019
<ul> <li>Executive Chair KidKraft, Inc.</li> <li>Chair, Holley Inc. &amp; Mid Ocean Ptrs. PE Consumer Group</li> <li>Former Dir. Hudson's Bay Co., HSNi &amp; Treehouse Foods</li> <li>Former: Roark Capital, TPG Capital, TPG Growth, Varsity Brands, Collective Brands, Cole Haan, J Crew, Popular Club Plan and more</li> <li>Pres. Appointee, House Advisory Council on Trade Policy Negotiation</li> </ul>	<ul> <li>Advisory Board Chair, APFI P&amp;G Franchising Initiatives</li> <li>Dir. Zion Healing and ASP UPF Holdings LP</li> <li>Exe. Counsel American Securities.</li> <li>Former: CEO of Mail Boxes Etc. (now The UPS Store), Chair of Intl. Franchise Assn. (IFA), Planet Fitness, Meineke Car Care Centers, Oreck Corp., Zig Ziglar, SkinPhD, Aspen Dental, WSI of Canada, Univ. of Missouri</li> <li>Marine Corps Captain, National Veterans' Admin., Marine Military Academy, Marine Corps Heritage Fdn.</li> </ul>	<ul> <li>Financial Advisor: Manufacturing Succession Holding, Universal Health and Multiomics</li> <li>Vice Chair of the Strategic Advisory Board of Aura Ventures</li> <li>Dir. Universal Health Group, Delta Dental of Arizona, Mobile Holding Properties, LLC and NorthStar Security</li> <li>Former: Deloitte &amp; Touche Mobile Holdings Properties Alkaline Water Co. NanoFlex Power Corp. Amazing Lash Studio CFO &amp; franchisee</li> </ul>	<ul> <li>Exe. Project Sponsor and former Chief HR Officer, Aspen Dental Mgmt</li> <li>HR &amp; Talent Acquisition Advisor, Bond Veterinary</li> <li>Former Dir. Refresh Mental Health Davis Vision Companies</li> </ul>	<ul> <li>Pres. &amp; CEO, The Joint Corp.</li> <li>Former Mgmt.: <ul> <li>Tasti D-Lite</li> <li>Great Hills Partners</li> <li>Mail Boxes, Etc. (now The UPS Store)</li> </ul> </li> <li>Director Intl.I Franchise Assn. (IFA)</li> <li>Chair, International Affairs Network (IAN)</li> </ul>	<ul> <li>EVP &amp; CTO, Learning Care Group</li> <li>Former Mgmt.: <ul> <li>Discount Tire Company</li> <li>Red Rock Resorts</li> <li>Starbucks Corp.</li> </ul> </li> <li>Technologent</li> </ul>	<ul> <li>Founder, Managing Partner, &amp; PM Glenhill Capital Advisors</li> <li>Dir. Ember Technologies &amp; Design within Reach</li> <li>Former Mgmt. or Dir.</li> <li>Centric Brands</li> <li>Restoration Hardware</li> <li>Cumberland Associates</li> <li>The Goldman Sachs Group</li> </ul>

BS, Ohio University MBA, University of Miami AB, University of Missouri-Columbia BS, Queens College MBA, Pace University

BS, Russell Sage College

BA, Univ. of Washington MA, University of London BE, U.S. Military Academy at West Point

BA, Wesleyan Univer 87 ty MBA, New York University

## **Revolutionizing Access to Chiropractic Care**

Features	Industry Problems	The Joint's Solutions				
Affordability (per appointment)	<sup>\$</sup> 64 Average <sup>1</sup>	<sup>\$</sup> 33 Average				
Convenient Locations	Medical Centers / Offices	Retail Locations				
Multiple Locations	Limited Locations	805 Clinics				
Walk-in / No Appointment	Appointments Required	No Appointments				
Insurance / Caps / Co-pays	Yes	Private Pay				
Inviting, Consumer-centric Design	Clinical	Approachable, Consumer Friendly				
Service Hours	Limited / Inconsistent	Open 6-7 Days + Nights & Weekends <sup>2</sup>				
Average Patient Visits per Clinic	112 per week <sup>3</sup>	347 per week <sup>4</sup>				



#### **Patient Demographics**

Median Age	36 Years	
Generation Mix	2021	Growth over 2020
Gen Z	16%	63%
Millennial	45%	38%
Gen X	27%	29%
Baby Boomer	12%	25%
Gender		
Female	49%	





<sup>1</sup> Patients who visited The Joint Chiropractic in 2021

# Transformative Opportunity for Chiropractors

	Industry	The Joint	
Annual Salary	Median \$81,240 <sup>1</sup>	Starting \$85,000 <sup>2</sup>	
Accessibility	<ul> <li>Appointments required</li> <li>Medical centers &amp; offices</li> <li>Traditional office hours</li> </ul>	<ul> <li>No appointments</li> <li>Clustered, high-visibility retail locations</li> <li>Open evenings + weekends<sup>3</sup></li> </ul>	
Practice & Insurance	<ul> <li>Challenges of managing a business without support</li> <li>Difficulty attracting new patients</li> <li>Insurance hassles</li> <li>Slow payment cycle</li> </ul>	<ul> <li>Proprietary CRM and POS software</li> <li>Ongoing training and coaching</li> <li>Ability to perfect technique</li> <li>Less administration</li> <li>Higher patient focus</li> <li>Better cash flow</li> </ul>	



#### Performance Metrics and Non-GAAP Measures

This presentation includes commonly discussed performance metrics. System-wide sales include sales at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

This presentation includes non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the Company's underlying operating performance and operating trends than GAAP measures alone. Reconciliations of net loss to EBITDA and Adjusted EBITDA are presented where applicable. The Company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses. The Company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase net gain, gain/(loss) on disposition or impairment, and stock-based compensation expenses.

EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are frequently used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the Company's financial statements filed with the SEC.



# Q3 2022 Segment Results as of Sept. 30, 2022

\$ in 000s

2022

	Corporate Clinics		Franchise Operations		llocated porate	ne Joint solidated
Total Revenues	\$	15,836	\$	10,765	\$ 1	\$ 26,603
Total Operating Costs		(16,128)		(5,570)	 (4,404)	(26,103)
Operating Income (Loss)		(292)		5,196	(4,403)	500
Other Income (Expense), net		(1)		-	 (24)	(25)
Loss Before Income Tax Expense		(293)		5,196	(4,427)	475
Total Income Taxes		-		-	 (16)	(16)
Net Income (Loss)		(293)		5,196	(4,412)	491
Net Interest		1		-	 24	25
Income Taxes		-		-	(16)	(16)
Total Depreciation and Amortization Expense		1,737		189	 86	2,012
EBITDA		1,445		5,385	(4,318)	2,512
Stock Based Compensation Exp		-		-	 306	306
Bargain Purchase Gain		-		-	-	-
Loss on Disposition/Impairment		264		-	0	264
Acquisition Expenses		-		-	 47	47
Adjusted EBITDA		1,709		5,385	 (3,965)	3,129



**Q3** 

# YTD 2022 Segment Results as of Sept. 30, 2022

\$ in 000s



	Clinics	Ор	Operations		porate	Consolidated		
Total Revenues	\$ 42,937	\$	31,160	\$	2	\$	74,099	
Total Operating Costs	 (43,354)		(17,356)		(12,591)		(73,302)	
Operating Income (Loss)	 (417)		13,804		(12,589)		797	
Other Income (Expense), net	 (4)		-		(57)		(61)	
Income (Loss) Before Income Tax Expense	 (421)		13,804		(12,646)		737	
Total Income Taxes	 -		-		107		107	
Net Income (Loss)	 (421)		13,804		(12,753)		630	
Net Interest	 4		-		57		61	
Income Taxes	-		-		107		107	
Total Depreciation and Amortization Expense	 4,543		549		249		5,341	
EBITDA	 4,126		14,353		(12,340)		6,139	
Stock Based Compensation Exp	 -		-		970		970	
Bargain Purchase Gain	-		-		-		-	
(Gain) Loss on Disposition/Impairment	360		-		0		360	
Acquisition Expenses	 -		-		78		78	
Adjusted EBITDA	 4,486		14,353		(11,292)		7,547	

Corporate

Franchise

Unallocated



The Joint

#### GAAP – Non-GAAP Reconciliation

#### \$ in 000s

	Quar	rter Ending	arter Ending	arter Ending	Qua	arter Ending		Quarter Ending Quarter Ending Quarter Ending										
		03/31/2021		06/30/2021		09/30/2021		12/31/2021			03/31/2022		06/30/2022		09/30/2022			
																	_	
		21-21		Q2-21		Q3-21		Q4-21	FY21		Q1-22		Q2-22		Q3-22	Q4-22		Y22
Total Revenue		17,548		20,219		20,992		22,101	80,860		22,439		25,057		26,603	-	74	4,099
Total Cost of Revenue		1,765		2,039		2,300		2,410	8,514		2,313		2,427		2,490	-	7	7,230
Gross Profit	\$	15,783	\$	18,180	\$	18,691	\$	19,691	\$72,346	\$	20,126	\$	22,630	\$	24,113	\$-	\$66	6,869
Sales & Marketing		2,489		3,133		2,882		2,921	11,424		3,287		3,840		3,539	-	10	0,667
Depreciation/Amortization Expense		1,170		1,443		1,662		1,814	6,089		1,629		1,700		2,012	-	5	5,341
Other Operating Expenses		10,186		11,611		12,812		14,936	49,546		15,379		16,589		18,056	-	50	0,023
Total Other Income (Expense)		13		25		(13)		(29)	(4)		(23)		(48)		(30)	-		(101)
Total Income Taxes		(364)		(666)		(614)		351	(1,293)		13		109		(16)	-		107
Net Income (Loss)	\$	2,315	\$	2,684	\$	1,937	\$	(360)	\$ 6,576	\$	(206)	\$	345	\$	491	\$-	\$	630
Net Interest		22		16		16		16	70		16		19		25	-		61
Income Taxes		(364)		(666)		(614)		351	(1,293)		13		109		(16)	-		107
Depreciation and Amortization Expense		1,170		1,443		1,662		1,814	6,089		1,629		1,700		2,012	-	5	5,341
EBITDA	\$	3,142	\$	3,477	\$	3,001	\$	1,821	\$11,441	\$	1,453	\$	2,174	\$	2,512	\$-	\$ e	6,139
Stock Based Compensation		246		284		297		229	1,056		324		340		306	-		970
Bargain Purchase Gain		-		-		-		-	-		-		-		-	-		-
(Gain) Loss on Disposition/Impairment		65		(44)		(4)		10	27		-		89		264	-		353
Acquisition Expenses		6		39		3		20	69		(0)		32		47	-		78
Adjusted EBITDA	\$	3,459	\$	3,756	\$	3,297	\$	2,080	\$12,593	\$	1,783	\$	2,635	\$	3,129	\$-	\$ 7	7,547



### **Contact Information**



#### Peter D. Holt, President & CEO peter.holt@thejoint.com The Joint Corp. | 16767 N. Perimeter Dr., Suite 240, Scottsdale, AZ 85260 | (480) 245-5960



Jake Singleton, CFO jake.singleton@thejoint.com The Joint Corp. | 16767 N. Perimeter Dr., Suite 240, Scottsdale, AZ 85260 | (480) 245-5960



#### Kirsten Chapman, LHA Investor Relations

thejoint@lhai.com LHA Investor Relations | 50 California Street, Suite 1500 | San Francisco, CA 94111 | (415) 433-3777



